AlTi Global, Inc. Class A (ALTI) Dividend History

AlTi Global, Inc. Class A (ALTI) is an investment firm focused on acquiring and managing private equity assets, including aerospace, defense, and related technology companies. The company emphasizes long-term value creation through strategic investments in innovative businesses within its targeted sectors.

520 Madison Ave, New York, NY, 10022
Phone: 212-461-6363
Website:

Dividend History

AlTi Global, Inc. Class A currently does not pay dividends

Company News

  • AlTi Global, Inc. (ALTI) Q1 Earnings and Revenues Miss Estimates

    AlTi Global, Inc. (ALTI) delivered earnings and revenue surprises of -66.67% and 17.38%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: BTCS
  • Howard Hughes Holdings (HHH) Reports Q1 Loss, Misses Revenue Estimates

    Howard Hughes Holdings (HHH) delivered earnings and revenue surprises of -51.43% and 19.89%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: HHH
  • Moody's (MCO) Tops Q1 Earnings and Revenue Estimates

    Moody's (MCO) delivered earnings and revenue surprises of 10.13% and 3.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: MCO
  • Globe Life (GL) Soars 20.2%: Is Further Upside Left in the Stock?

    Globe Life (GL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

    Zacks Investment Research
    Featured Companies: GL
  • Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday

    U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia. Enliven Therapeutics shares surged 26% to $24.97 on Thursday. Here are some other big stocks recording losses in today’s session. Rallybio Corporation (NASDAQ: RLYB) shares gained 89.6% to $3.09 after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Alpine Immune Sciences, ...

    Benzinga
    Featured Companies: ANAB ELVN FRO FVRR GCT GYRE IAG JANX NEXN NRIX RLYB STEP
Dividend data last updated 06/07/2025 20:46:18 UTC